Q-omics provides the consensus-scored KDM1A profile across patient tissues and cancer cell-line models. KDM1A expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, KDM1A is differentially expressed in 16, with the highest sampling consensus in BLCA. Additionally, KDM1A protein abundance shows 35,018 significant protein co-abundance associations, with the highest sampling consensus in HNSC. Together, these results highlight LIHC, BLCA, and HNSC as cancer lineages where KDM1A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KDM1A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KDM1A survival associations across molecular data types. KDM1A RNA expression shows survival associations in the most cancer types (21), followed by mutation status (7) and mass-spec protein abundance (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KDM1A RNA expression–survival associations across cancer types. High KDM1A expression shows unfavorable associations in LIHC, ACC, KICH and SARC, but favorable associations in SCLC and COAD. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for KDM1A RNA expression.
This table summarizes KDM1A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 10. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for KDM1A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KDM1A shows higher tumor expression in BLCA, HNSC, COAD, LUAD, LUSC and LIHC. The BLCA box plot shows higher KDM1A RNA expression in tumor versus normal tissue (log2 FC = +1.702, t-test p < 0.001).
This table shows molecular features associated with KDM1A in patient tissues and cancer cell lines. In patient samples, KDM1A shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set. In cancer cell lines, KDM1A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and BLOOD_Leukemia.
